Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease

Inclusion Criteria: * Male and female patients 20-80 years old * Diagnosis of idiopathic interstitial pneumonia or secondary to connective tissue diseases interstitial lung disease, based on: * Clinical symptoms \> 12 months duration, * Histologically diagnosed or diagnostic chest HRCT features of interstitial pneumonia * Forced Vital Capacity (FVC) ≥ 40% predicted and Diffusing Lung Capacity (DLCO) ≥20% * Loss more than 10% of FVC (L) and DLCO during the last 12 months * Signed informed consent. Exclusion Criteria: * Diagnosis of an interstitial lung disease other than idiopathic interstitial pneumonia or connective tissue disease associated with interstitial lung disease (sarcoidosis, pulmonary alveolar proteinosis, lymphangioleiomyomatosis, pulmonary amyloidosis, exposure-related lung disease etc) * Obstructive lung disease: FEV1/FVC \< 0.70 * Clinically significant medical condition, in the opinion of the investigator, may compromise the results of the study * Evidence of active infection within 4 week prior to enrollment * History of malignancy \< 5 years prior to enrollment * Unable to cooperate with any study procedures * Pregnant or breast-feeding * Treatment with antiinflammatory or antifibrotic drugs including oral steroids, cytostatic drugs, pirfenidone, D penicillamine, colchicine, tumor necrosis factor α blockers, imatinib, interferon γ, monoclonal antibodies \< 6 months prior to randomization. * Active listing for transplant of any organ. * Known history of alcohol abuse within 1 year prior to enrollment * Participation in another clinical trial